NCT05334472View on ClinicalTrials.gov

A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis

CompletedOBSERVATIONAL

Enrollment

105

Participants

Timeline

Start Date

November 24, 2021

Primary Completion Date

February 15, 2023

Study Completion Date

February 15, 2023

Conditions

Multiple Sclerosis

Interventions

OTHER

Kesimpta

There was no treatment allocation. Patients administered Kesimpta by prescription that started before inclusion of the patient into the study were enrolled.

Trial Locations (1)

07936

Novartis Investigative Site, East Hanover